In this “Ask Me Anything” (AMA) episode, Peter explores the topic of gray-market peptides, one of the most requested and most confusing topics he’s covered on The Drive. Peptides sit at the intersection of biological plausibility, clinical promise, and aggressive commercialization, and are often marketed as cutting-edge therapies for everything from muscle repair and longevity to cosmetic enhancement. Rather than promoting or dismissing peptides wholesale, Peter lays out a clear, repeatable framework for evaluating any peptide or drug—covering mechanism, intended effects, safety, dosing, and alternatives. He distinguishes FDA-approved peptide therapeutics from the loosely regulated “peptides” common in biohacking culture; examines the strengths and limitations of animal and human evidence; unpacks manufacturing, gray-market sales, “research use only” labeling, and third-party testing; addresses oral peptides and absorption challenges; and explains how patents and incentives shape which compounds advance through clinical pipelines. The discussion concludes with a sober look at what would need to change for peptides to become broadly usable therapies, where legitimate peptide therapeutics may expand next, and which areas of medicine stand to benefit most right now.

Full show notes can be found here: https://peterattiamd.com/ama83/

We discuss:

Setting the framework for evaluating peptides, and explaining the goal of this discussion [3:15];
What peptides are: basic definitions, biological roles, and therapeutic foundations [5:30];
A framework for evaluating peptides: mechanism, evidence, safety, and regulatory context [10:00];
Peptide case study—SS-31: mechanism of action, approved use in Barth syndrome, and other claimed effects [18:15];
Does the mechanistic rationale for SS-31 translate into measurable benefits? [22:15];
SS-31 continued: safety considerations, gray market risks, the balance of risk versus reward, and why it belongs in bucket #3 [26:00];
Peptide case study—melanotan-II: claimed effects, mechanism of action, safety, and side effects [30:45];
Melanotan-II continued: weighing the potential risks versus benefits and why it belongs in bucket #2 [36:30];
Peptide case study—CJC-1295: growth hormone–stimulating mechanism, claimed effects, and limited human data [40:15];
CJC-1295 continued: dosing uncertainty, risk-reward analysis, lack of long-term safety data, limited approved options, and why it belongs in bucket #2 [49:30];
Peptide case study—BPC 157: uncertain origins, broad claims, and weak mechanistic evidence [57:45];
BPC 157 continued: review of human evidence, lack of replication of animal data, safety considerations, risk-reward analysis, and why it belongs in bucket #1 [1:03:15];
Other popular “gray market” peptides and why they mostly fail when under scrutiny [1:11:15];
How the evidence on peptides compares to rapamycin, and why the lack of data is the biggest concern [1:20:00];
Understanding peptide regulation: FDA approval, supplement oversight, and the risks of gray-market compounds [1:23:00];
Inside the gray market: how peptides are sold, regulated, and why testing cannot guarantee safety [1:26:45];
Limitations of oral peptides, and examples of peptides in bucket #4 [1:31:45];
The future of peptides: real therapeutic potential versus hype in the wellness market [1:35:00]; and
More.

#387 - AMA #83: Peptides—evaluating the science, safety, and hype in a rapidly growing field

The Peter Attia Drive - Private Subscriber Feed (🔓 for Vijay Khakhria)